GlobeNewswire Inc.··Eupraxia Pharmaceuticals Inc.Eupraxia's EE Drug Hits Key Milestone With 90% Tissue Improvement in Phase Data
Eupraxia Pharmaceuticals reports positive Phase 1b/2a data for EP-104GI in eosinophilic esophagitis, showing 90% tissue improvement and strong safety profile.
EPRXbiotechdrug delivery